First Ever Real-World Evidence of Eversense 365 Presented at ATTD Demonstrates Sustained Performance and Positive Impact Throughout One-Year of Wear

Core Insights - The Eversense 365 Continuous Glucose Monitoring (CGM) system has demonstrated sustained performance and positive real-world impact over a full year, showcasing strong patient adherence and effective glycemic outcomes [1][2][3] Group 1: Product Performance - Eversense 365 achieved an average transmitter wear time of 93.8%, with consistent results across the first and second six-month periods, indicating reliable use of the system [4] - The mean Glucose Management Indicator (GMI) was reported at 7.14%, and the mean Time in Range (TIR) was 66%, reflecting effective glycemic control [4] - Over 75% of users met hypoglycemic targets, highlighting the system's accuracy in low glucose ranges, which is critical for patient safety [5] Group 2: Age Group Analysis - The analysis indicated that Eversense 365 provided positive outcomes across all age groups, with the >65 year-old population achieving a mean GMI of 6.99% and a mean TIR of over 70% [5] - Young adults (aged 18-25) also showed promising results, with a mean GMI of 7.3% and over 90% average wear time, indicating strong adherence [6] Group 3: Market Expansion and Future Prospects - Senseonics plans to launch Eversense 365 in select European markets following its CE mark approval in January 2026, building on its commercial momentum in the US [9] - The company is also analyzing early data from the twiist™ Automated Insulin Delivery (AID) system, which is compatible with Eversense 365, showing encouraging glucose outcomes [7][8]